New psoriasis drug put to the test in Real-World setting
NCT ID NCT06512337
Summary
This study aims to see how well the medication deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. It will follow 150 patients who are newly starting this treatment to measure improvements in their skin condition and quality of life. The goal is to gather real-world evidence on the drug's effectiveness outside of controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, 102218, China
Contact Phone: •••-•••-••••
-
DaLian Dermatosis Hospital
RECRUITINGDalian, Liaoning, 116021, China
Contact Phone: •••-•••-••••
-
Dermatology Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510091, China
Contact Phone: •••-•••-••••
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-••••
-
The Affiliated Hospital of Hebei University of Engineering
RECRUITINGHandan, Hebei, 056029, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.